Tempest Therapeutics, Inc. (TPST) Stock Profile — Insider Trades & Financials

Net Income-$4.0M

EPS$-5.71

Market Cap$22.4M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Matthew Angel

CEO & Executive Director

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Founded: 2011
Employees: 21
Headquarters: Brisbane, California, United States

⚡

Core Efficiency

ROE?

-60.30%

ROA?

-23.75%

D/E Ratio?

1.54

📊

Profitability Ratios

Current Ratio?

2.50

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 24, 2026 (in 137 days)

Annual Report (10-K) — Based on filing pattern

Aug 24, 2026

Predicted10-K

Mar 30, 2026

10-KQ4 20255d after period end

Nov 5, 2025

10-QQ3 20256d after period end

Aug 11, 2025

10-QQ2 20257d after period end

May 13, 2025

10-QQ1 20255d after period end

Apr 30, 2025

10-K/AQ4 20245d after period end

Nov 12, 2024

10-QQ3 20244d after period end

Aug 8, 2024

10-QQ2 20243d after period end

May 9, 2024

10-QQ1 20243d after period end

Loading company sections...

Tempest Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness